PL3157552T3 - Polipeptydy syntac i ich zastosowania - Google Patents

Polipeptydy syntac i ich zastosowania

Info

Publication number
PL3157552T3
PL3157552T3 PL15809277T PL15809277T PL3157552T3 PL 3157552 T3 PL3157552 T3 PL 3157552T3 PL 15809277 T PL15809277 T PL 15809277T PL 15809277 T PL15809277 T PL 15809277T PL 3157552 T3 PL3157552 T3 PL 3157552T3
Authority
PL
Poland
Prior art keywords
syntac polypeptides
syntac
polypeptides
Prior art date
Application number
PL15809277T
Other languages
English (en)
Polish (pl)
Inventor
Ronald D. SEIDEL III
Rodolfo J. Chaparro
Brandan S. Hillerich
Scott J. Garforth
Steven C. Almo
Original Assignee
Albert Einstein College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Of Medicine filed Critical Albert Einstein College Of Medicine
Publication of PL3157552T3 publication Critical patent/PL3157552T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15809277T 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania PL3157552T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013715P 2014-06-18 2014-06-18
EP15809277.5A EP3157552B1 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof
PCT/US2015/035777 WO2015195531A2 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
PL3157552T3 true PL3157552T3 (pl) 2020-05-18

Family

ID=54936224

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15809277T PL3157552T3 (pl) 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania
PL18212801T PL3480213T3 (pl) 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18212801T PL3480213T3 (pl) 2014-06-18 2015-06-15 Polipeptydy syntac i ich zastosowania

Country Status (15)

Country Link
US (5) US20170058015A1 (enExample)
EP (3) EP3483179B1 (enExample)
JP (4) JP6652932B2 (enExample)
KR (1) KR102252119B1 (enExample)
CN (3) CN113248624B (enExample)
AU (3) AU2015277460B2 (enExample)
DK (2) DK3480213T3 (enExample)
ES (2) ES2770330T3 (enExample)
HU (2) HUE048076T2 (enExample)
IL (3) IL248979B (enExample)
PL (2) PL3157552T3 (enExample)
PT (2) PT3480213T (enExample)
SG (2) SG11201609876TA (enExample)
TW (3) TWI696633B (enExample)
WO (1) WO2015195531A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3640375A3 (en) 2012-12-11 2020-07-29 Albert Einstein College of Medicine Methods for high throughput receptor/ligand identification
WO2017151818A2 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US20190046648A1 (en) * 2016-03-03 2019-02-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017266905B2 (en) * 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
KR20190019068A (ko) * 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
CN109843931A (zh) * 2016-08-11 2019-06-04 昆士兰医学研究所理事会 免疫调节化合物
WO2018119114A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) * 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
WO2018170168A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
WO2018187190A1 (en) * 2017-04-06 2018-10-11 Albert Einstein College Of Medicine, Inc. Precision activation of hiv-specific ctls to eliminate reactived latent t cells
KR102738427B1 (ko) * 2017-06-12 2024-12-06 시나이 헬스 시스템 전신 면역억제가 불필요한 동종 이식편 내성
CN107266581B (zh) * 2017-06-13 2021-07-09 四川大学 藏猪il-12重组质粒增强pcv2疫苗免疫佐剂的制备方法及应用
CN117820498A (zh) * 2017-08-10 2024-04-05 盖立复诊断解决方案公司 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒
WO2019051094A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. ANTIGEN PRESENTATION POLYPEPTIDES AND METHODS OF USE
KR20200064085A (ko) 2017-09-07 2020-06-05 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
BR112020004535A2 (pt) * 2017-09-07 2020-09-08 Cue Biopharma, Inc. peptídeos moduladores de células t multiméricos e métodos de uso destes
TW201925235A (zh) * 2017-09-07 2019-07-01 美商信號生物製藥公司 具有化學結合位點之抗原呈現多肽及其使用方法
KR20190065234A (ko) * 2017-11-30 2019-06-11 그리폴스 다이어그노스틱 솔루션즈 인크. 면역 관문 억제제인 pd-1 및 pd-l1에 대한 항체 치료를 모니터링하기 위한 면역분석 및 조작된 단백질
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
DK3772927T3 (da) 2018-03-24 2025-02-17 Regeneron Pharma Genetisk modificerede mus eller rotter til generering af terapeutiske antistoffer mod peptid¿MHC-komplekser, fremgangsmåde til fremstilling og anvendelser deraf
US20220047710A1 (en) * 2018-09-12 2022-02-17 Washington University Single chain constructs
CA3123102A1 (en) * 2018-12-13 2020-06-18 Sinai Health System Immunomodulatory cells and uses thereof
WO2020132368A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
KR20210104700A (ko) * 2018-12-19 2021-08-25 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
JP7691927B2 (ja) * 2019-03-06 2025-06-12 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
JP2022522405A (ja) * 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
WO2020243315A1 (en) * 2019-05-29 2020-12-03 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020257191A1 (en) * 2019-06-19 2020-12-24 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20220066075A (ko) * 2019-09-20 2022-05-23 큐 바이오파마, 인크. T-세포 조절 폴리펩타이드 및 이의 사용 방법
CA3146917A1 (en) * 2019-10-23 2021-04-29 Anish SURI T-cell modulatory chimeric molecules and methods of use thereof
JP2023500573A (ja) * 2019-10-23 2023-01-10 キュー バイオファーマ， インコーポレイテッド 改変された細胞傷害性ｔ細胞及びその使用方法
US12091440B2 (en) 2019-12-20 2024-09-17 Regeneron Pharmaceuticals, Inc. IL2 and peptide-MHC complex fusion proteins and methods of use thereof
US20230076204A1 (en) * 2020-02-18 2023-03-09 Institute For Systems Biology Single chain trimer mhc class ii nucleic acids and proteins and methods of use
WO2021168388A1 (en) * 2020-02-21 2021-08-26 3T Biosciences, Inc. Yeast display libraries, associated compositions, and associated methods of use
US20230126784A1 (en) * 2020-03-06 2023-04-27 Albert Einstein College Of Medicine A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity
CA3178427A1 (en) * 2020-05-12 2021-11-18 Lg Chem, Ltd. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN116096405A (zh) 2020-05-12 2023-05-09 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
WO2021254491A1 (en) * 2020-06-19 2021-12-23 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal expressing a b2m/fcrn fusion protein
EP4210736A4 (en) * 2020-09-09 2024-10-23 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS AND METHODS OF USE THEREOF
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
CN112725273A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk细胞及其制备方法和应用
CN112725284A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk滋养层细胞及其应用
CN112852744A (zh) * 2021-01-27 2021-05-28 河南省华隆生物技术有限公司 一种nk滋养层细胞及其制备方法和应用
CN112779224A (zh) * 2021-01-27 2021-05-11 河南省华隆生物技术有限公司 一种表达细胞因子组合物的nk滋养层细胞及其制备方法和应用
EP4308142A4 (en) * 2021-03-19 2025-04-16 Cue Biopharma, Inc. T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
WO2022216974A1 (en) * 2021-04-07 2022-10-13 Repertoire Immune Medicines, Inc. Peptide-mhc-immunoglobulin multimers and methods of use thereof
JP2024519500A (ja) * 2021-05-07 2024-05-14 インスティチュート フォー システムズ バイオロジー 単鎖三量体ｍｈｃクラスｉ核酸およびタンパク質ならびに使用方法
JP2024534787A (ja) 2021-08-16 2024-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規なｉｌ２７受容体アゴニスト及びその使用方法
WO2023023641A2 (en) * 2021-08-20 2023-02-23 3T Biosciences, Inc. Peptide-hla-b*35 libraries, associated compositions, and associated methods of use
WO2023126544A1 (en) * 2022-01-03 2023-07-06 Aarhus Universitet Proteinaceous compound for generating specific cytotoxic t-cell effect
WO2023205728A2 (en) * 2022-04-21 2023-10-26 Institute For Systems Biology Soluble single-chain dimers from cleavable single chain trimers
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
EP4654982A1 (en) 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
KR20250166361A (ko) 2023-02-28 2025-11-27 리제너론 파아마슈티컬스, 인크. Mhc 도메인 및 항원 펩티드를 포함하는 펩티드-mhc 착물 및 면역 세포 항원 표적화 모이어티를 포함하는 다중특이적 분자
WO2025081106A2 (en) * 2023-10-12 2025-04-17 Vanderbilt University Nanobody vaccine compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
ATE314482T1 (de) 1993-10-25 2006-01-15 Canji Inc Rekombinante adenoviren-vektor und verfahren zur verwendung
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
EP2336167B1 (en) * 2001-03-14 2019-05-29 Dako Denmark A/S MHC molecule constructs and their uses for diagnosis and therapy
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
EP2361930A3 (en) * 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
CA2887486A1 (en) * 2012-11-30 2014-06-05 Roche Glycart Ag Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
KR20200064085A (ko) * 2017-09-07 2020-06-05 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Also Published As

Publication number Publication date
JP2020022491A (ja) 2020-02-13
HUE047255T2 (hu) 2020-04-28
US20170058015A1 (en) 2017-03-02
TWI696633B (zh) 2020-06-21
CN106456733A (zh) 2017-02-22
IL266570A (en) 2019-07-31
TWI795740B (zh) 2023-03-11
CN113248623A (zh) 2021-08-13
PL3480213T3 (pl) 2020-05-18
EP3483179B1 (en) 2020-09-16
IL248979B (en) 2020-06-30
CA2947489A1 (en) 2015-12-23
US20210238254A1 (en) 2021-08-05
SG10202006338UA (en) 2020-08-28
BR112016027897A2 (pt) 2017-10-24
AU2015277460B2 (en) 2020-10-08
EP3157552B1 (en) 2019-10-23
IL275307A (en) 2020-07-30
KR20170030484A (ko) 2017-03-17
SG11201609876TA (en) 2017-01-27
JP6652932B2 (ja) 2020-02-26
DK3157552T3 (da) 2020-01-13
IL275307B (en) 2022-03-01
JP2017519491A (ja) 2017-07-20
AU2021204594B2 (en) 2024-05-09
AU2019203442A1 (en) 2019-06-06
CN113248624A (zh) 2021-08-13
US20200377569A1 (en) 2020-12-03
US20210047384A1 (en) 2021-02-18
TWI722576B (zh) 2021-03-21
CN106456733B (zh) 2021-03-16
EP3480213B1 (en) 2019-11-13
EP3483179A1 (en) 2019-05-15
US20180282392A1 (en) 2018-10-04
TW201946933A (zh) 2019-12-16
AU2019203442B2 (en) 2021-04-08
JP6995151B2 (ja) 2022-02-21
ES2767259T3 (es) 2020-06-17
JP2020072733A (ja) 2020-05-14
EP3157552A4 (en) 2017-11-22
AU2021204594A1 (en) 2021-07-29
CN113248624B (zh) 2025-02-07
IL248979A0 (en) 2017-01-31
PT3157552T (pt) 2020-01-22
KR102252119B1 (ko) 2021-05-17
EP3480213A1 (en) 2019-05-08
IL266570B (en) 2020-06-30
WO2015195531A3 (en) 2016-02-25
HUE048076T2 (hu) 2020-07-28
EP3157552A2 (en) 2017-04-26
DK3480213T3 (da) 2020-02-17
AU2015277460A1 (en) 2016-11-24
PT3480213T (pt) 2020-02-04
JP7331075B2 (ja) 2023-08-22
ES2770330T3 (es) 2020-07-01
JP6652680B2 (ja) 2020-02-26
WO2015195531A2 (en) 2015-12-23
TW202124435A (zh) 2021-07-01
JP2022046544A (ja) 2022-03-23
TW201613966A (en) 2016-04-16

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
IL275307B (en) Syntac polypeptides and their uses
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
PL3653221T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
DK4089113T3 (da) Polypeptider
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
EP4135127C0 (en) MICRO-ASSEMBLY STRATEGIES AND DEVICES FOR COMPOUNDS
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
IL254591A0 (en) Polypeptides
IL250502A0 (en) New polypeptides
DK3099791T3 (da) Protein
PT3337506T (pt) Combinações e suas utilizações
DK3184633T3 (da) Modificeret beta-galaktosidase
HRP20182029T1 (hr) Uti-fuzijski proteini
DK3099793T3 (da) Protein
GB201410031D0 (en) Polypeptides and uses thereof
EP3298014A4 (en) S1pr2 antagonists and uses therefor
DK3412700T3 (da) Forbindelser
DE202014105547U8 (de) Steckverbinder und Steckverbindung